| Niraparib in patients with newly diagnosed advanced ovarian cancer A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ... New England Journal of Medicine 381 (25), 2391-2402, 2019 | 1688 | 2019 |
| A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer M Koneru, R O’Cearbhaill, S Pendharkar, DR Spriggs, RJ Brentjens Journal of translational medicine 13, 1-11, 2015 | 306 | 2015 |
| A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti–PD-1 agent pembrolizumab PS Adusumilli, MG Zauderer, I Rivière, SB Solomon, VW Rusch, ... Cancer discovery 11 (11), 2748-2763, 2021 | 263 | 2021 |
| Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ... The Lancet Oncology 20 (4), 570-580, 2019 | 213 | 2019 |
| Pembrolizumab plus chemotherapy in advanced endometrial cancer RN Eskander, MW Sill, L Beffa, RG Moore, JM Hope, FB Musa, R Mannel, ... New England Journal of Medicine 388 (23), 2159-2170, 2023 | 164 | 2023 |
| Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center JJ Mueller, QC Zhou, A Iasonos, RE O'Cearbhaill, FA Alvi, A El Haraki, ... Gynecologic oncology 140 (3), 436-442, 2016 | 127 | 2016 |
| Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002) AD Santin, W Deng, M Frumovitz, N Buza, S Bellone, W Huh, S Khleif, ... Gynecologic oncology 157 (1), 161-166, 2020 | 125 | 2020 |
| Clinical utility of prospective molecular characterization in advanced endometrial cancer TE Soumerai, MTA Donoghue, C Bandlamudi, P Srinivasan, MT Chang, ... Clinical Cancer Research 24 (23), 5939-5947, 2018 | 123 | 2018 |
| Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors R O'Cearbhaill, Q Zhou, A Iasonos, RA Soslow, MM Leitao, C Aghajanian, ... Gynecologic oncology 116 (3), 424-429, 2010 | 112 | 2010 |
| Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent. PS Adusumilli, MG Zauderer, VW Rusch, R O'Cearbhaill, A Zhu, D Ngai, ... Journal of Clinical Oncology 37 (15_suppl), 2511-2511, 2019 | 90 | 2019 |
| Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma MM Leitao Jr, ML Hensley, RR Barakat, C Aghajanian, GJ Gardner, ... Gynecologic oncology 124 (3), 558-562, 2012 | 86 | 2012 |
| Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or … VD Sioulas, MB Schiavone, D Kadouri, O Zivanovic, KL Roche, ... Gynecologic oncology 145 (1), 15-20, 2017 | 79 | 2017 |
| A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer KN Moore, CC Gunderson, P Sabbatini, DS McMeekin, ... Gynecologic oncology 154 (2), 294-301, 2019 | 77 | 2019 |
| Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study O Zivanovic, DS Chi, Q Zhou, A Iasonos, JA Konner, V Makker, ... Journal of Clinical Oncology 39 (23), 2594-2604, 2021 | 74 | 2021 |
| Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results cohort study, 2000–2013 A Oseledchyk, MM Leitao Jr, J Konner, RE O’Cearbhaill, D Zamarin, ... Annals of Oncology 28 (12), 2985-2993, 2017 | 74 | 2017 |
| Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis MM Leitao Jr, O Zivanovic, DS Chi, ML Hensley, R O'Cearbhaill, ... Gynecologic oncology 125 (2), 409-413, 2012 | 73 | 2012 |
| COVID‐19 outcomes of patients with gynecologic cancer in New York City OD Lara, RE O’Cearbhaill, MJ Smith, ME Sutter, A Knisely, J McEachron, ... Cancer 126 (19), 4294-4303, 2020 | 59 | 2020 |
| Is it time to centralize ovarian cancer care in the United States? RA Cowan, RE O’Cearbhaill, GJ Gardner, DA Levine, KL Roche, ... Annals of surgical oncology 23, 989-993, 2016 | 58 | 2016 |
| The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin … R O'Cearbhaill, Q Zhou, A Iasonos, ML Hensley, WP Tew, C Aghajanian, ... Gynecologic oncology 116 (3), 326-331, 2010 | 57 | 2010 |
| Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer RA Cowan, RE O’Cearbhaill, O Zivanovic, DS Chi International Journal of Hyperthermia 33 (5), 548-553, 2017 | 56 | 2017 |
